Analysis of IL-6 serum levels and CAR-T cell specific digital PCR in the context of cytokine release syndrome (CRS)

Following the Swissmedic approval of Kymriah ® (tisagenlecleucel; Novartis) 2018 for chimeric antigen receptor (CAR)-T cell therapy for adults with relapsed or refractory (r/r) B-lineage ALL and high-grade B-cell lymphomas after failure of ≥2 therapy lines, followed by the approval of Yescarta® (axicabtagen ciloleucel, Kite/Gilead) by Swis smedic in 2019, a growing number of Swiss centers have established CAR-T therapy. In addition, CAR-T therapy is currently explored for other hematologic malignancies, e.g.

Source: Experimental Hematology - July 12, 2020 Category: Hematology Authors: Thomas Pabst, Raphael Joncourt, Evgenii Shumilov, Alexander Heini, Gertrud Wiedemann, Myriam Legros, Katja Seipel, Christof Schild, Katarzyna Jalowiec, Behrouz Mansouri, Michaela Fux, Urban Novak, Naomi Porret, Sacha Zeerleder, Ulrike Bacher Tags: Brief Communication Source Type: research